Status:
UNKNOWN
Contrast Ultrasound Dispersion Imaging (CUDI) as a Diagnostic Modality in the Diagnosis of Renal Cell Carcinoma
Lead Sponsor:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Conditions:
Kidney Cancer
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Introduction The current limitations of renal cell carcinoma (RCC) imaging form a major deficit in the diagnostic pathway. Contrast Enhanced UltraSound (CEUS) has the potential to improve RCC detectio...
Eligibility Criteria
Inclusion
- age ≥ 18 years
- signed informed consent
- scheduled for a radical- or partial nephrectomy for the suspicious of a renal tumor.
Exclusion
- Earlier treatment of renal masses
- History of any clinically evidence of cardiac right-to-left shunts
- Severe pulmonary hypertension (pulmonary artery pressure \>90 mmHg) or uncontrolled systemic hypertension or respiratory distress syndrome
- Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study
- Is incapable of understanding the language in which the information for the patient is given
- Tumor cannot be visualized/localized on ultrasound imaging
- Previous hypersensitivity allergic reactions
- Known allergy of macrogol 4000, distearoylphosphatidylcholine, dipalmitoylphosphatidylglycerol Sodium, Palmitic acid
- Use of dobutamine or conditions suggesting cardiovascular instability where dobutamine is contraindicated.
- Pregnant or breastfeeding
Key Trial Info
Start Date :
December 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2021
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04669613
Start Date
December 30 2020
End Date
April 1 2021
Last Update
December 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Amsterdam UMC
Amsterdam, North Holland, Netherlands, 1105AZ